English
Français
我们先进的基因治疗技术亚搏全站app下载pitalizes on our differentiated knowledge of direct-to-brain administration of AAV vectors, allowing us to precisely target the causes of disease.
Extraordinary progress in developing therapies for CNS diseases with lead programs in neurodegenerative lysosomal storage disorders.
Our team is committed to developing pioneering therapies that will transform the lives of children affected by these devastating diseases.
Our team is committed to fulfilling gene therapy’s potential by developing pioneering therapies that will transform the lives of children affected by these devastating diseases.
News, press releases, and more.
Paris, France —03 June 2022 at 6:00 pm CET — Lysogene (FR0013233475 – LYS),…
• Promising efficacy data in young patients with persistent increase or stabilization in 3 main…
Cash and cash equivalents of €10.7 million[1] as of 31 March 2022 Paris, France —…
Paris, France — 21 April 2022 at 08:00 am CEST — Lysogene (FR0013233475 – LYS),…
Paris, France — 20 April 2022 at 08:00 am — Lysogene (FR0013233475 – LYS), a…
Lysogene exercises its option after a conclusive research collaboration period Paris, France — 12 April 2022…
Paris, France – 31 March 2022 at 8:00 am CET – Lysogene (FR0013233475 – LYS),…
Topline data of the main cohort of AAVance clinical trial expected in Q3 2022 Stabilization…
New positive biomarker data from 16 patients treated with LYS-SAF302 showing reduction in heparan sulfate…
Third patient treated in the global clinical trial with LYS-GM101 gene therapy program in GM1…
Valuable information designed to provide knowledge and insights to patients, families, and caregivers.
Mucopolysaccharidosis type IIIA (MPS IIIA), or Sanfilippo syndrome type A, is a rare neurodegenerative lysosomal storage disorder characterized by intractable behavioral problems and developmental regression that typically appears in infancy or early childhood.
亚博登录首页GM1 gangliosidosis或降落的疾病,是一种罕见的inherited neurodegenerative lysosomal storage disorder characterized by severe cognitive and motor developmental delays.
Fragile X syndrome (FXS) is the most common inherited cause of autism spectrum disorder and affects approximately 1 in 4,000 to 5,000 boys and 1 in 8,000 girls.
Neuronopathic Gaucher and Parkinson’s disease are both associated with mutations in the GBA1 gene and cause neurological symptoms.
The EURORDIS Company Award for Innovation recognizes Lysogene as a pioneering gene therapy company which has established itself among major players driving European-led innovation, in just over ten years.
